Dear Doctor Letter (Rote-Hand-Brief) on Onivyde® (liposomal irinotecan): risk of medication error due to change in the expression of strength and dose calculation
2019.10.25
Active substance: irinotecan liposomal
Servier Deutschland GmbH in agreement with the European Medicines Agency (EMA) and the Federal Institute for Drugs and Medical Devices (BfArM) would like to inform you that the expression of strength of Onivyde® has changed. Be aware of the risk of medication error and ascertain that the dose has been calculated correctly. The amount of active ingredient in the vial is unchanged.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN